Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 3/20 | 0.36 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | USP14 | P54578 | 4/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098331 | 0.82 | TRPV1 (0.35) | TRPV1TDP2ALDH1A2ALDH1A3CYP11B2 | |
| SCHEMBL1993850 | 0.78 | POLB (0.36) | CYP11B2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4093348 | 0.76 | CTSS (0.39) | CTSS | |
| SCHEMBL4430107 | 0.76 | CTSS (0.37) | TRPV1TDP2ALDH1A2ALDH1A3CYP11B2 | |
| SCHEMBL5438324 | 0.75 | ALDH1A2 (0.38) | ALDH1A2ALDH1A3CTSS | |
| SCHEMBL2235680 | 0.75 | CTSS (0.36) | TRPV1TDP2ALDH1A2ALDH1A3CTSS | |
| SCHEMBL4520031 | 0.75 | JAK2 (0.36) | TRPV1TDP2ALDH1A2ALDH1A3CTSS | |
| SCHEMBL3169031 | 0.74 | CTSS (0.36) | CYP11B2CTSSUSP14 | |
| SCHEMBL4426575 | 0.74 | CTSS (0.36) | TRPV1TDP2ALDH1A2ALDH1A3CTSS | |
| SCHEMBL4516517 | 0.74 | JAK2 (0.37) | ALDH1A2ALDH1A3CTSSUSP14PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866310-B1 | 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2012-07-11 | — | — | EP | disclosed |
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-1866310-A1 | 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006100520-A1 | 2,3-SUBSTITUTED FUSED PYRIMIDIN-4(3H)-ONES AS VR1 ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152242-A1 | 2,3-Substituted Fused Pyrimidin -4 (3H)-Ones as VR1 Antagonists | NR2C2, NR3C2, NR2E3 | TRPV1 784/4885TDP2 4432/4885ALDH1A2 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.